Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071555 | 0.78 | SNCA (0.46) | ALDH1A1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL386809 | 0.78 | MEN1 (0.49) | ALDH1A1TSHRMEN1KMT2ACYP3A4 | |
| SCHEMBL7770634 | 0.78 | MEN1 (0.49) | ALDH1A1TSHRMEN1KMT2ACYP3A4 | |
| SCHEMBL9798232 | 0.75 | ALDH1A1 (0.39) | ALDH1A1TSHRCYP3A4IDO1MAPT | |
| Styrene SCHEMBL4908731 | 0.73 | ALDH1A1 (0.64) | ALDH1A1TSHRMEN1KMT2ACYP3A4 | |
| SCHEMBL28340911 | 0.72 | IDO1 (0.57) | ALDH1A1TSHRMEN1KMT2AIDO1 | |
| SCHEMBL2769032 | 0.71 | ALDH1A1 (0.36) | ALDH1A1TSHRMEN1KMT2AIDO1 | |
| SCHEMBL29135403 | 0.71 | IDO1 (0.36) | ALDH1A1TSHRMEN1KMT2AIDO1 | |
| SCHEMBL7054866 | 0.71 | ALDH1A1 (0.36) | ALDH1A1TSHRMEN1KMT2AIDO1 | |
| SCHEMBL93706 | 0.71 | RELA (0.47) | ALDH1A1TSHRMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716386-A | Novel exosome inhibitor and preparation method thereof | 北京和理咨询有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-9809822-B2 | Triptolide derivatives and preparation method and use thereof | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-11-07 | — | — | US | claimed |
| US-20160362691-A1 | TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | HONG KONG BAPTIST UNIVERSITY (HK) | 2016-12-15 | — | — | US | claimed |
| US-20130116203-A1 | ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | claimed |
| US-7572907-B2 | Methods and compounds for polynucleotide synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2009-08-11 | — | — | US | claimed |
| US-20080312164-A1 | ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | claimed |
| WO-2008008954-A2 | ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIOS CONTAINING SAME | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-01-17 | — | — | WO | claimed |
| EP-1717242-A1 | Polynucleotide synthesis | Agilent Technologies, Inc. (US) | 2006-11-02 | — | — | EP | claimed |
| US-20060247430-A1 | Methods and compounds for polynucleotide synthesis | AGILENT TECHNOLOGIES, INC. | 2006-11-02 | — | — | US | claimed |
| WO-2005002514-A2 | COMPOUNDS HAVING INHIBITIBE ACTIVITY OF PHOSPHATIDYLINOSITOL 3-KINASE AND METHODS OF USE THEREOF | ECHELON BIOSCIENCES INCORPORATED (US) | 2005-01-13 | — | — | WO | claimed |
| US-5532357-A | Method for preparing N-monosubstituted and N,N'-disubstituted unsymmetrical cyclic ureas | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-02 | — | — | US | claimed |
| EP-0691961-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF HIV DISEASE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-17 | — | — | EP | claimed |
| EP-0686151-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-12-13 | — | — | EP | claimed |
| WO-1994022840-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF HIV DISEASE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | claimed |
| WO-1994019329-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-09-01 | — | — | WO | claimed |
| EP-0607334-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS. | DU PONT MERCK PHARMA (US) | 1994-07-27 | — | — | EP | claimed |
| WO-1994008977-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF AIDS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-04-28 | — | — | WO | claimed |
| WO-1993007128-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-15 | — | — | WO | claimed |
| WO-1991003449-A1 | ISOMERIZATION OF ALK-2-ENYL ETHERS | GAF CHEMICALS CORPORATION (US) | 1991-03-21 | — | — | WO | claimed |
| EP-0073566-A1 | Methods and compositions for combating soil pests | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-03-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247430-A1 | Methods and compounds for polynucleotide synthesis | POLN, POLRMT, POLM | ALDH1A1 3888/4885TSHR 3633/4885MEN1 3222/4885 |
| US-20080312164-A1 | ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | GGCT, GSTK1, GCLC | ALDH1A1 1045/4885TSHR 4560/4885MEN1 2240/4885 |
| US-20130116203-A1 | ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | GGCT, GSTK1, GSTA1 | ALDH1A1 896/4885TSHR 4240/4885MEN1 2511/4885 |
| US-20160362691-A1 | TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | TPD52L2, TRDMT1, MCTS1 | ALDH1A1 2399/4885TSHR 325/4885MEN1 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.